Evidence map›Paper›PMID 39960520›Full record

ArticleJournal of neurology2025

Correction: Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02).

Barry J Byrne, Benedikt Schoser, Priya S Kishnani, Drago Bratkovic, Paula R Clemens, Ozlem Goker-Alpan, Xue Ming, Mark Roberts, Matthias Vorgerd, Kumaraswamy Sivakumar and 10 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Barry J ByrneUniversity of Florida, Gainesville, FL, USA. barry.byrne@ufl.edu.ORCID http://orcid.org/0000-0002-7302-1756
Benedikt SchoserFriedrich-Baur-Institute at the Department of Neurology, LMU University Hospital, LMU Munich, Munich, Germany.
Priya S KishnaniDuke University Medical Center, Durham, NC, USA.
Drago BratkovicPARC Research Clinic, Royal Adelaide Hospital, Adelaide, SA, Australia.
Paula R ClemensDepartment of Neurology, University of Pittsburgh School of Medicine and VA Pittsburgh Healthcare System, Pittsburgh, PA, USA.
Ozlem Goker-AlpanLysosomal and Rare Disorders Research and Treatment Center, Fairfax, VA, USA.
Xue MingNeurology, Rutgers New Jersey Medical School, Newark, NJ, USA.
Mark RobertsSalford Royal NHS Foundation Trust, Salford, UK.
Matthias VorgerdDepartment of Neurology, University Hospital Bergmannsheil, Heimer Institute for Muscle Research, Bochum, Germany.
Kumaraswamy SivakumarNeuromuscular Clinic and Research Center, Phoenix, AZ, USA.
Ans T van der PloegErasmus MC University Medical Center, Rotterdam, Netherlands.
Mitchell GoldmanAmicus Therapeutics, Inc., Princeton, NJ, USA.
Jacquelyn WrightAmicus Therapeutics, Inc., Princeton, NJ, USA.
Fred HoldbrookAmicus Therapeutics, Inc., Princeton, NJ, USA.
Vipul JainAmicus Therapeutics, Inc., Princeton, NJ, USA.
Elfrida R BenjaminAmicus Therapeutics, Inc., Princeton, NJ, USA.
Franklin JohnsonAmicus Therapeutics, Inc., Princeton, NJ, USA.
Sheela Sitaraman DasAmicus Therapeutics, Inc., Princeton, NJ, USA.
Yasmine WasfiAmicus Therapeutics, Inc., Princeton, NJ, USA.
Tahseen MozaffarUniversity of California, Irvine, Irvine, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39960520
PMCPMC11832724

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.